|
1) Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008; 70: 418-24
|
|
|
|
2) Serdaroglu P, Deymeer F, Parman Y. Prevalence of sporadic inclusion body myositis(s-IBM) in Turkey: A muscle biopsy based survey. Neuromuscul Disord. 2007; 17: 849
|
|
|
|
|
|
3) Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci. 2008; 15: 1350-3
|
|
|
|
|
|
4) Wilson FC, Ytterberg SR, St Sauver JL, et al. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008; 35: 445-7
|
|
|
|
|
|
5) Needham M, Mastaglia FL, Garlepp MJ. Genetics of inclusion-body myositis. Muscle Nerve. 2007; 35: 549-61
|
|
|
|
|
|
6) Scott AP, Allcock RJ, Mastaglia F, et al. Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52. 1. Neuromuscul Disord. 2006; 16: 311-5
|
|
|
|
|
|
7) Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008; 79: 1056-60
|
|
|
|
|
|
8) Needham M, Hooper A, James I, et al. Apolipoprotein ε alleles in sporadic inclusion body myositis: a reappraisal. Neuromuscul Disord. 2008; 18: 150-2
|
|
|
|
|
|
9) Dalakas MC, Rakocevic G, Shatunov A, et al. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol. 2007; 61: 466-75
|
|
|
|
|
|
10) Matsuura E, Umehara F, Nose H, et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol. 2008; 67: 41-9
|
|
|
|
|
|
11) Salajegheh M, Rakocevic G, Raju R, et al. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology. 2007; 69: 1672-9
|
|
|
|
|
|
12) De Paepe B, Creus KK, De Bleecker JL. Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann N Y Acad Sci. 2007; 1109: 441-53
|
|
|
|
|
|
13) Tateyama M, Fujihara K, Misu T, et al. CCR7＋ myeloid dendritic cells together with CCR7＋ T cells and CCR7＋ macrophages invade CCL19＋ nonnecrotic muscle fibers in inclusion body myositis. J Neurol Sci. 2009; 279: 47-52
|
|
|
|
|
|
14) Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology. 2002; 59: 1170-82
|
|
|
|
|
|
15) Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain. 2008; 131(Pt 5): 1228-40
|
|
|
|
|
|
16) Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3β. Ann Neurol. 2008; 64: 15-24
|
|
|
|
|
|
17) Olivé M, Janué A, Moreno D, et al. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol. 2009; 68: 262-73
|
|
|
|
|
|
18) Terracciano C, Nogalska A, Engel WK, et al. In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med. 2008; 45: 773-9
|
|
|
|
|
|
19) Vattemi G, Nogalska A, King Engel W, et al. Amyloid-β42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol. 2009; 117: 569-74
|
|
|
|
|
|
20) Jayaraman M, Kannayiram G, Rajadas J. Amyloid toxicity in skeletal myoblasts: Implications for inclusion-body myositis. Arch Biochem Biophys. 2008; 474: 15-21
|
|
|
|
|
|
21) Shtifman A, Ward CW, Laver DR, et al. Amyloid-β protein impairs Ca(2＋) release and contractility in skeletal muscle. Neurobiol Aging. 2008 Dec 22. [Epub ahead of print]
|
|
|
|
|
|
22) Askanas V, McFerrin J, Alvarez RB, et al. β APP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Neuroreport. 1997; 8: 2155-8
|
|
|
|
|
|
23) Li J, Yin C, Okamoto H, et al. Proteomic analysis of inclusion body myositis. J Neuropathol Exp Neurol. 2006; 65: 826-33
|
|
|
|
|
|
24) Hutchinson DO, Jongbloed B. Two-dimensional gel electrophoresis in inclusion body myositis. J Clin Neurosci. 2008; 15: 440-4
|
|
|
|
|
|
25) Banwell BL, Engel AG. αB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology. 2000; 54: 1033-41
|
|
|
|
|
|
26) Wojcik S, Engel WK, McFerrin J, et al. AβPP-overexpression and proteasome inhibition increase αB-crystallin in cultured human muscle: relevance to inclusion-body myositis. Neuromuscul Disord. 2006; 16: 839-44
|
|
|
|
|
|
27) Lünemann JD, Schmidt J, Schmid D, et al. β-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol. 2007; 61: 476-83
|
|
|
|
|
|
28) Lünemann JD, Schmidt J, Dalakas MC, et al. Macroautophagy as a pathomechanism in sporadic inclusion body myositis. Autophagy. 2007; 3: 384-6
|
|
|
|
|
|
29) Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy-a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol. 2005; 171: 87-98
|
|
|
|
|
|
30) Malicdan MC, Noguchi S, Nishino I. Autophagy in a mouse model of distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Autophagy. 2007; 3: 396-8
|
|
|
|
|
|
31) McFerrin J, Engel WK, Askanas V. Cultured inclusion-body myositis muscle fibers do not accumulate β-amyloid precursor protein and can be innervated. Neurology. 1999; 53: 2184-7
|
|
|
|
|
|
32) Morosetti R, Broccolini A, Sancricca C, et al. Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging. 2008 Sep 25. [Epub ahead of print]
|
|
|
|
|
|
33) Wojcik S, Nogalska A, McFerrin J, et al. Myostatin precursor protein is increased and associates with amyloid-β precursor protein in inclusion-body myositis culture model. Neuropathol Appl Neurobiol. 2007; 33: 238-42
|
|
|
|
|
|
34) Nogalska A, Wojcik S, Engel WK, et al. Endoplasmic reticulum stress induces myostatin precursor protein and NF-κB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol. 2007; 204: 610-8
|
|
|
|
|
|
35) McFarlane C, Hennebry A, Thomas M, et al. Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp Cell Res. 2008; 314: 317-29
|
|
|
|
|
|
36) Chen X, Ghribi O, Geiger JD. Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis. Am J Physiol Regul Integr Comp Physiol. 2008; 294: 829-35
|
|
|
|
|
|
37) Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995; 45: 1302-4
|
|
|
|
|
|
38) Griggs RC. The current status of treatment for inclusion-body myositis. Neurology. 2006; 66(2 Suppl 1): S30-2
|
|
|
|
|
|
39) Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008; 67: 1670-7
|
|
|
|
|
|
40) Lindberg C, Trysberg E, Tarkowski A, et al. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003; 61: 260-2
|
|
|
|
|
|
41) Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009; 132(Pt 6): 1536-44
|
|
|
|
|
|
42) Kitazawa M, Vasilevko V, Cribbs DH, et al. Immunization with amyloid-β attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci. 2009; 29: 6132-41
|
|
|
|
|
|
43) Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002; 420: 418-21
|
|
|
|
|
|
44) Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008; 63: 561-71
|
|
|
|
|
|
45) Rodino-Klapac LR, Haidet AM, Kota J, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009; 39: 283-96
|
|
|
|
|